Wordt geladen...
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site
A major priority in HIV vaccine research is the development of an immunogen to elicit broadly neutralizing antibodies (NAbs). Monoclonal antibody (mAb) b12 is one of now several broadly neutralizing mAbs that bind epitopes overlapping the CD4-binding site (CD4bs) on HIV-1 gp120 and that serve as tem...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3733221/ https://ncbi.nlm.nih.gov/pubmed/22142583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2011.11.089 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|